Adverse events
| . | Number of patients with available data . | VEN monotherapy, % . | VEN combination, % . | P . |
|---|---|---|---|---|
| TLS (overall) | 321 | 11.5 | 5.8 | .07 |
| Grade 3 neutropenia | 233 | 40.4 | 34 | .45 |
| Grade 3 thrombocytopenia | 232 | 30.8 | 23 | .27 |
| Neutropenic fever | 232 | 8.6 | 2.3 | .37 |
| Grade 3 diarrhea | 230 | 8.7 | 5.1 | .36 |
| Discontinuation rate | 321 | 41 | 39 | .77 |
| . | Number of patients with available data . | VEN monotherapy, % . | VEN combination, % . | P . |
|---|---|---|---|---|
| TLS (overall) | 321 | 11.5 | 5.8 | .07 |
| Grade 3 neutropenia | 233 | 40.4 | 34 | .45 |
| Grade 3 thrombocytopenia | 232 | 30.8 | 23 | .27 |
| Neutropenic fever | 232 | 8.6 | 2.3 | .37 |
| Grade 3 diarrhea | 230 | 8.7 | 5.1 | .36 |
| Discontinuation rate | 321 | 41 | 39 | .77 |